Mar 17, 2026Nutrition

Semaglutide vs. Bariatric Surgery for Heart Health

Does semaglutide protect the heart as well as bariatric surgery? Compare MACE, heart failure, blood pressure, and the limits of current evidence.

semaglutidetirzepatideglp-1 agonistsbariatric surgery

Read article →

Mar 14, 2026Obesity Pharmacology

GLP-1 Receptor Agonists for Obesity: Benefits and Risks

GLP-1 drugs deliver unusually large weight loss and may improve cardiovascular outcomes, but GI effects, lean mass, surgery, and long-term use complicate choice.

semaglutidetirzepatideglp-1 agonistsweight loss

Read article →

Mar 14, 2026Nutrition

GLP-1 Heart Benefits Are Real. The RAS Mechanism Isn’t.

GLP-1 drugs reduce cardiovascular events in high-risk diabetes, but the proposed renin-angiotensin mechanism remains unproven.

semaglutideglp-1 agonistcardiovascular diseasetype 2 diabetes

Read article →

Mar 13, 2026Sleep

Tirzepatide for Sleep Apnea: Big Results, Unproven Mechanism

Tirzepatide cuts sleep-apnea severity in trials, largely through weight loss. Does it help beyond weight loss? The evidence has not proved it.

tirzepatidesleep apneaglp-1weight loss

Read article →

Mar 3, 2026Nutrition

Intermittent Fasting vs Calorie Restriction: What Actually Wins

Time-restricted eating works mostly by cutting calories. New meta-analyses rank alternate-day fasting highest among IF plans, with real caveats.

intermittent fastingcalorie restrictiontime-restricted eatingbody composition

Read article →

Mar 1, 2026Hormones

GLP-1 Drugs and Heart Failure: Benefit Seems to Depend on Obesity

GLP-1 drugs cut cardiovascular death broadly, but heart failure hospitalization benefit appears limited to obese patients. Here's what the evidence shows.

glp-1semaglutidetirzepatidehfpef

Read article →

Feb 28, 2026Glp1 Agonists

SELECT’s Undercovered Result: Fewer Hospitalizations on Semaglutide

SELECT made headlines for fewer heart attacks and strokes. The quieter result: semaglutide also cut hospital admissions and hospital days in high-risk obesity.

semaglutideglp-1 agonistweight losscardiovascular protection

Read article →

← PreviousPage 3 of 3